Urologic Cancers News
The approval was based on data from several clinical trials, including the phase 3 PACIFIC trial and the phase 3 CASPIAN trial.
Sometimes the distinctions between cancer treatment groups are a little blurry. Here’s a guide to their definitions and origins.
RCC vaccines are predominantly being developed using autologous tumor cells, dendritic cells, genetically modified tumor cells, and peptides.
Modified dosing of lenvatinib-everolimus did not improve tolerability and may have modestly decreased efficacy compared with standard dosing in advanced RCC.
A phase 2 trial has been initiated to evaluate a HIF-2α inhibitor for the treatment of advanced RCC after progression with another therapy.
A modified dosing regimen of nivolumab-ipilimumab for patients with advanced RCC did not provide additional benefit compared with standard dosing.
A phase 3 randomized placebo-controlled trial is recruiting to evaluate nivolumab plus ipilimumab among patients with localized RCC at risk of relapse after nephrectomy.
A phase 3 randomized active-controlled trial will evaluate atezolizumab plus cabozantinib among patients with advanced RCC whose disease progressed with ICIs.
A double-blind, placebo-controlled phase 3 trial is planned to evaluate cabozantinib plus nivolumab and ipilimumab as first-line treatment for advanced clear cell RCC..
Patients who were Black, had higher incomes, or who had undergone surgery were less likely to receive palliative care.
Surgical delays due to COVID-19 may be safe for some patients with localized RCC, and are unlikely to compromise survival for some individuals.
RCC histology was associated with survival after treatment with tremelimumab, according to results of a post hoc analysis of a pilot trial.
A phase 3, randomized, active-controlled trial will evaluate the efficacy and safety of a HIF-2α inhibitor for the second-line treatment of clear cell RCC.
The prospective study showed that after 4 years, complete resection of the tumor for children with local lymph node involvement (no metastasis) delivered an overall survival rate of 91.4%.
A recent HHS announcement spurred concern that FDA oversight of LDTs was eroding, threatening patient safety — but the reality is less dire.
Laparoscopic partial nephrectomy and percutaneous cryoablation for cT1 renal tumors are associated with similar 5-year rates of metastasis-free and overall and cancer-specific survival.
New data show that complete metastasectomy for selected cases of metastatic renal cell carcinoma (mRCC) prolongs survival in the postcytokine therapy era.
Several gene signatures were associated with outcomes among patients with advanced clear cell RCC, but not non-clear cell RCC.
Gene signatures were identified as potential predictive biomarkers for outcomes with nivolumab among patients with advanced ccRCC in an analysis of the NIVOREN GETUG-AFU 26 trial.
Circulating tumor DNA analysis of genomic alterations was concordant with tissue genomic analysis in a cohort of patients with advanced RCC.